Shire Eyes Lifitegrast For Growth But Still Gets Dry Reception
Executive Summary
The specialty pharma expressed confidence about the late-stage dry-eye drug lifitegrast at a Dec. 10 R&D day, but analysts remain wary about whether Shire can hit sales goals based on its current pipeline.
You may also be interested in...
New Shire CEO Has Big Ophthalmology Plans; SARcode Sets The Stage
With its third acquisition this year, Shire gains Phase III Lifitegrast in development for dry eye disease. It expects to launch the product in the U.S. in 2016.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.